More interesting data from the San Francisco meeting


As mentioned previously, there were over 200 new presentations on prostate cancer at the ASCO Genitourinary Cancers meeting in San Francisco on Friday and Saturday last week, and there is no way we can report on most of these. However, for what it is worth, here is a very brief summary of some of the original papers that looked to be among the more interesting. We have provided a link to the abstract for each relevant presentation.

Trump et al. provided a detailed report on the safety of the endothelin receptor antagonist zibotentan (ZD4054) when used in combination with doectaxel in a phase I clinical trial. There was no evidence that docetaxel increased the toxicity profile of zibotentan or vice versa.

Keizman et al. reported on the potential to use lenalidomide (Revlimid/Celgene) at two different doses to delay the progression of biochemically recurrent prostate cancer (stage M0 disease).

Small et al. presented a poster on the feasibility of intermittent chemotherapy (with docetaxel + prednisone) as a mechanism for treatment of metastatic, castration-resistant prostate cancer (CRPC).

Gravis et al. reported on the safety data from a Phase III clinical trial of chemohormonal therapy for treatment of hormone-naive, metastatic prostate cancer. This trial compared androgen deprivation therapy (any one of three types) + docetaxel to androgen deprivation therapy alone. There are no available outcome data reported as yet.

Harden et al. reported on the impact of prostate cancer treatment on the patients’ partners at 2 years post-treatment.

Crook et al. reported on quality of life of patients who participated in the (under-enrolled) SPIRIT trial at 5 years follow-up. The brachytherapy patients seemed to do better than the radical prostatectomy patients.

Klotz et al. examined the effect of different “triggers” for initiation of active treatment in their series of 450 patients on active surveillance, and suggested that most of the potential triggers actually suggest active treatment in an unnecessarily and unacceptably high proportion of patients.

Sylvester et al. reported 15-year survival data from some of the earliest iodine-125 brachytherapy patients treated by the Seattle group, and showing that there was a high level of biochemical relapse-free survival (> 80 percent) and an overall survival of 37 percent in a group of men who had a mean age of 70 years at time of treatment.

Nguyen et al. provided data on the increasing utilization of higher cost forms of treatment (minimally invasive surgery, intensity-modulated radiation therapy, etc.) for localized prostate cancer from 2002 through 2007.

Kenfield et al. provided further data to support the premise that regular, vigorous physical activity may reduce overall (“all-cause”) mortality among prostate cancer patients.

Kantoff et al. provided follow-up data from the IMPACT trial on the survival benefit of treatment with sipuleucel-T at an estimated median follow-up of 36.5 months. These data confirm the original survival data initially presented at the American Urological Association meeting in 2009.

Antonarakis et al. analyzed 15-year follow-up data on the overall survival of men with biochemical failure after radical prostatectomy in the CPDR database, and confirmed that PSA doubling time is the best determinant of all-cause survival in such patients over time.

Zivi et al. reported on the long-term follow-up of patients treated in early Phase II clinical trials of abiraterone acetate, commenting that this drug can apparently be given for long periods of time without any need for concurrent corticosteroids like prednisone.

We would conclude by again noting that abstracts of all of the original papers presented at this symposium are accessible on line at no cost to the reader under two general headings:

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: